Numerical scoring for the BILAG-2004 index - Wikidata - awgldk - TriplyDB

Numerical scoring for the BILAG-2004 index

Numerical scoring for the BILAG-2004 index

http://www.wikidata.org/entity/Q34056232

about

Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research From BILAG to BILAG-based combined lupus assessment-30 years on Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus.The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally.Pain, Fatigue, and Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus Validation of the Lupus Nephritis Clinical Indices in Childhood-Onset Systemic Lupus Erythematosus.Mercury in Hair Is Inversely Related to Disease Associated Damage in Systemic Lupus Erythematosus Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus.Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus Measuring outcomes in systemic lupus erythematosus clinical trials.Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythemato Top 10 things to know about lupus activity measures.Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients.The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index.Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study.Attribution in the assessment of nervous system disease in SLE.Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort.A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).Phagocyte activity in the peripheral blood of pregnant women with systemic lupus erythematosus and in the cord blood of their newborns.Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.Validation of Patient-Reported Outcomes Measurement Information System Short Forms for Use in Childhood-Onset Systemic Lupus Erythematosus.Pain predicts poorer health-related quality of life in childhood-onset systemic lupus erythematosus: a cohort study.Avoiding diagnostic pitfalls in neuropsychiatric lupus: the importance of attribution.Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register.Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life.Fatigue and depression predict reduced health-related quality of life in childhood-onset lupus.Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients with Associated Sjögren's Syndrome: Post-hoc Analyses from the EMBODY Trials.Improved strategies for designing lupus trials with targeted therapies: learning from 65 years of experience.Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus.Assessments of fatigue and disease activity in patients with systemic lupus erythematosus enrolled in the Phase 2 clinical trial with blisibimod.

P2860

Q26799223-27408744-99A6-4077-BF7B-8F8B756B1C00 Q28081809-DE7C738B-1420-4937-A000-EC8217E082F6 Q28268159-8D4659F7-0E0E-4DC0-AF11-431858F67690 Q28660706-4F15B342-4C3A-4440-AA07-F8A139B4600C Q33659103-F15DBBA8-624D-4A6F-9B3E-25E396AEFB82 Q36331877-B8614F51-6BAA-43FA-9B76-F7FB7AF1D4B6 Q36470477-118DEFF2-5E56-4409-8CD5-EE95A549AC50 Q36484106-45739541-6E4D-4DDC-A9C5-96E716BD76D5 Q36513087-98598E06-998D-4E45-9EDF-22B01A6EAF78 Q37312374-D7D0F63F-21A8-47A2-B747-EDDEB3A17D32 Q37316490-13EFA520-F747-4FD0-B261-2EE3D8B27D7F Q37398870-6FB9A3E1-EE15-4A93-ADBF-DEFAF73EFA8F Q37633396-2FC89A22-C69E-4B51-9FC5-277D7CD8C0B3 Q37633408-2DC205BE-9608-462E-8DAB-937254D8B15A Q37914899-2DCDF188-1FF4-49F6-AC5E-3B8C6E072E2D Q38010353-95E31C73-05D8-4FEE-A64A-2ABC8B6AD473 Q38100735-DE817CEF-F80E-4861-B251-FB218D5F06E6 Q38690330-0C1A87A5-E5FB-4C2F-B2D6-7FD1182B85D8 Q39095546-DF1CEA32-2DD1-4409-AAC1-1B937EC4CC4C Q39429702-4F002794-1960-4C5C-B6FF-CB836026184B Q41028325-C673D8BA-D3BE-4CD0-9842-83181A7B89AC Q42579446-4475EE02-83C1-464B-9565-51C47B5E7D94 Q45812853-74E08C8D-852C-42BC-904B-E58C8DA1E80C Q46055629-D38B062F-CE03-48D2-8729-45229C965B17 Q46373068-125320B4-6ACC-4FEB-AFE4-7AE5D9F8E692 Q47108999-266A3A8B-B342-46D6-976A-5EFC42AD97FC Q47151723-D564108A-1F57-4DF8-90B8-57BC04346385 Q47360317-C0AA0C75-4538-49BD-86FC-B263B1B29126 Q47566238-B8742BFE-B8FC-4D42-BACE-75612E04AA3D Q47687376-18E316C0-65F3-4F64-9C39-BB09CFEC7EB0 Q47778526-0F48C586-77FE-4E5F-80E9-9AA5DE73822B Q47841267-EED5E2FE-735B-41FB-B2BF-681B97A59CA7 Q49577334-0A16369A-21DD-46C0-9E69-47B5A3F5CCE1 Q50493859-8F37220C-5CF7-4BD5-BF57-54D9A88528DC Q52837753-AF0B1C01-148C-4284-BD4C-68C793F6DCDC Q52862110-2E8A6567-3115-4138-8A4C-C0A71918DCE0

P2860

Numerical scoring for the BILAG-2004 index

http://www.wikidata.org/entity/Q34056232

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Numerical scoring for the BILAG-2004 index

@ast

Numerical scoring for the BILAG-2004 index

@en

Numerical scoring for the BILAG-2004 index

@nl

type

label

Numerical scoring for the BILAG-2004 index

@ast

Numerical scoring for the BILAG-2004 index

@en

Numerical scoring for the BILAG-2004 index

@nl

prefLabel

Numerical scoring for the BILAG-2004 index

@ast

Numerical scoring for the BILAG-2004 index

@en

Numerical scoring for the BILAG-2004 index

@nl

P1433

Q34056232-E369E7D5-0F58-4A14-976F-00A74740B2A9

P1476

Q34056232-32CAB6D2-C96F-495F-B00C-4AA8C7328E5F

P2093

Q34056232-08E1B5C4-F91A-497C-BCDA-BDE0AA8AC3AE

Q34056232-16B7CFDE-A941-4A38-A6B9-60E53B122523

Q34056232-5B86946D-516C-4032-AC68-0FF05E6C369F

Q34056232-812C8A50-470E-44DB-BD04-94899C9CA0A6

Q34056232-9202097F-F621-406D-9951-F0FCF4FA7152

Q34056232-9D7A3EE3-76A3-4027-A7B7-16C2636CA022

Q34056232-B2A34142-7ED7-45CC-8BE1-C406300AA8B3

Q34056232-BBDC63A4-F250-4B0A-A9FB-75A25C7F130F

Q34056232-BF0E2DAD-DC0F-4AC5-9983-E0577F40DA1E

Q34056232-D6C05405-E553-4FF2-BAA8-D4F123E3CAE0

P2860

Q34056232-1FD2642A-1A16-4911-B441-67CB0E303E20

Q34056232-256EADB5-EEFA-4E66-AD3F-6E354CB650DD

Q34056232-2F969FE3-9159-44A2-B684-D14032D0C3EF

Q34056232-570997E2-D6EC-4B9D-B2B0-B85E16CE4E58

Q34056232-D148BB2D-8FB6-4F72-AB04-BD7F9BAC60AB

P304

Q34056232-D8173774-B12F-4844-9D25-6B9DB6BFBDFB

P31

Q34056232-2D7E8FE0-C812-4B27-AC0F-153D491EFB1E

P356

Q34056232-37BE617A-7A0D-495D-B38C-88810DA16644

P433

Q34056232-2002A73F-8651-4CA6-9394-6366571EABAF

P478

Q34056232-EB20FE5C-9901-47B1-A0E0-3D7F138D802C

P50

Q34056232-1134496C-4C70-451B-BF9C-EF085ACCB475

Q34056232-B4B1CD32-6CDB-47CD-A832-111F245081A3

Q34056232-C93557B7-BBB2-4E60-B536-1D6E11E49E89

Q34056232-E9316891-ADAC-4F73-A32D-351E8A681D91

Q34056232-F224CBD4-6177-4B5A-A024-879D770B5B5D

P577

Q34056232-588FD350-93C3-4E90-B9A3-902DC4AFA501

P5875

Q34056232-D7A8BE40-8017-4F65-8DBB-EED52CEC592D

P698

Q34056232-11DB500B-4506-4C73-B8A9-F9D1AFE2C0AA

P932

Q34056232-17E4AB0A-5049-48AA-BDD1-D8E0C40D9092

P356

P1433

P1476

Numerical scoring for the BILAG-2004 index

@en

P2093

Anisur Rahman

http://www.w3.org/2001/XMLSchema#string

Athiveeraramapandian Prabu

http://www.w3.org/2001/XMLSchema#string

Bridget Griffiths

http://www.w3.org/2001/XMLSchema#string

Chee-Seng Yee

http://www.w3.org/2001/XMLSchema#string

David D'Cruz

http://www.w3.org/2001/XMLSchema#string

Lee-Suan Teh

http://www.w3.org/2001/XMLSchema#string

Lynne Cresswell

http://www.w3.org/2001/XMLSchema#string

Mohammed Akil

http://www.w3.org/2001/XMLSchema#string

Neil McHugh

http://www.w3.org/2001/XMLSchema#string

Yasmeen Ahmad

http://www.w3.org/2001/XMLSchema#string

P2860

The 1982 revised criteria for the classification of systemic lupus erythematosus

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus.

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity

Numerical scoring for the Classic BILAG index

P304

1665-1669

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/RHEUMATOLOGY/KEQ026

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

David A. Isenberg

Vernon Farewell

Caroline Gordon

Munther A. Khamashta

P577

2010-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41561973

http://www.w3.org/2001/XMLSchema#string

P698

20181671

http://www.w3.org/2001/XMLSchema#string

P932

2919194

http://www.w3.org/2001/XMLSchema#string